Eosinophilic & Rare Disease Cooperative
Public records show a registered, tax-exempt organization in good standing.
What it says it does
Provide education and tools for people with rare disease.
- Income
- $351,488
- Spending
- $121,072
- Spent on programs
- 86%
- Reserves
- 28.9 months of spending
- Largest source of income
- donations and private grants, 99%
- Employees
- 1
- Volunteers
- 1
- Highest pay
- $64,566, ceo
Source: Form 990 for the year ending December 31, 2025, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Financial health
Strong: 100 out of 100. Higher than 81% of charities in its peer group (diseases, $250k to $1m).
Reserves
35 of 35Spendable reserves would cover 28.9 months of spending.
Debt
20 of 20It owes 0% of what it owns.
Living within its means
15 of 15Income exceeded spending by 66% of income.
Income trend
15 of 15Income rose 178% on the year before.
Spending floor
15 of 1586% of spending went to programs and raising each dollar of donations cost 0 cents.
Source: Form 990 for the year ending December 31, 2025, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Governance
Good: 83 out of 100. Higher than 60% of charities in its peer group (diseases, $250k to $1m).
Independent board
25 of 258 of 8 voting board members are independent.
Conflict of interest policy
15 of 15Has a written conflict of interest policy.
Whistleblower policy
0 of 8Reports no written whistleblower policy.
Record keeping policy
7 of 7Has a written policy on keeping and destroying records.
Board minutes
5 of 5Keeps minutes of board meetings.
Board sees the tax return
10 of 10Gave the board a copy of this return before filing it.
Pay set independently
5 of 5Sets its chief executive's pay through independent review and comparison.
Independent check of accounts
6 of 15Its accounts were not audited or reviewed by an independent accountant.
No reported misuse
10 of 10Reports no diversion of assets, excess benefits or loans to insiders.
Source: Form 990 for the year ending December 31, 2025, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Impact evidence
Describes programs. Its tax return describes what it does but we have found no measurable results in it.
Programs described in its return (4)
- $47,106 spent. HEAT Kits: Disease-specific Hospital Emergency Advocacy and Treatment Kits (HEAT Kits) that put plain-language, expert-reviewed information directly into the hands of patients and healthcare. HEAT Kits enable patients to engage in the healthcare community with confidence, even when not feeling well. Distributed for five rare diseases across the country and sent via PDF internationally.
- $24,191 spent. Livestream educational sessions bring people face to face with pharmacists, experts, and treatment developers to answer real questions about access, treatment decisions, and insurance. We avoid jargon, and encourage engagement with the presenter. Each session becomes enduring education on ERDC's YouTube platform, so the answers keep helping long after the livestream ends.Rare Candor Podcast: Unscripted conversations with real people, clinicians, and advocates about what it actually means to live with or care for someone with a rare disease. Available on Spotify and Apple, it's storytelling as advocacy, proof that the most powerful education comes from people telling the truth about their own lives.
- $22,260 spent. ANCA Vasculitis Decision Tree: A step-by-step decision making and planning platform that walks people with GPA, MPA, or EPGA through a personalized path from diagnosis to emergency decision-making, backed by a formal white paper written for journal submission. It gives clinicians and patients alike a clear, print-ready guide built from the patterns our community has lived through again and again.
- $10,962 spent. Public Policy: ERDC shows up where treatment access is actually decided with legislators and regulators, not just in the doctor's office. We've submitted formal comment letters, briefed congressional staff, and organized alongside national partners to oppose the withdrawal of essential medications and push back on pricing frameworks that leave 95% of rare diseases unprotected.
Source: Form 990 for the year ending December 31, 2025, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Legitimacy checks
Is it registered with the IRS? Passed.
Listed in the IRS master file of tax-exempt organizations as a 501(c)(3) charitable organization.
Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.
Has the IRS revoked its tax-exempt status? Passed.
Not on the IRS automatic revocation list.
Source: Automatic revocation of exemption list, Internal Revenue Service, file dated October 13, 2026.
Are donations tax-deductible? Passed.
On the IRS list of organizations eligible to receive tax-deductible contributions.
Source: Publication 78 data: organizations eligible for tax-deductible contributions, Internal Revenue Service, file dated October 13, 2026.
Is it keeping up with its IRS filings? Passed.
Most recent return on file covers the year ending December 2025.
Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.
How long has it been tax-exempt? Passed.
Recognized by the IRS since July 2021.
Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.
Is it in good standing with state regulators? Passed.
Not on California's list of charities barred from soliciting. Other states are not yet checked.
Source: May Not Operate or Solicit for Charitable Purposes list, California Attorney General, Registry of Charities and Fundraisers, file dated October 21, 2026.
Ratings and checks are our reading of public records, using the published method. They are not a statement about anyone's honesty. If you work for this organization, you can send corrections or results, confirm you want gifts through Veridonate, or ask to be removed from giving.